Graff L, Burnel D
Laboratoire de Chimie Générale Appliquée à la Médecine, Faculté de Médecine, Université Henri Poincaré, Nancy I, Vandoeuvre les Nancy, France.
Res Commun Mol Pathol Pharmacol. 1995 Sep;89(3):373-88.
The aim of this study was to highlight a possible new non-aluminum phosphate-binder to limit hyperphosphatemia in patients with renal failure. Lanthanum chloride hydrate was evaluated as a dietary phosphate binder in rats. Aluminum chloride hexahydrate was evaluated as a reference. Animals were divided in five groups (6 animals per group): 1 control group (C), 2 aluminum groups (Al1 and Al2), receiving different doses of aluminum chloride hexahydrate and 2 lanthanum groups (La1 and La2), receiving different doses of lanthanum chloride hydrate. During the treatment, urine and stools were collected. At the end of the treatment animals were sacrificed and plasma and different organs were collected (liver, spleen, kidneys, brain and femur). To highlight the possible transfer of lanthanum in rat tissues, a long-term (100 days) study was carried with a high dose. At the end of the treatment, lanthanum determinations were carried out on several tissues (liver, spleen, kidneys, brain, femur and lungs). Determinations of phosphorus and calcium levels in plasma indicated that lanthanum chloride hydrate showed as good results as aluminum chloride hexahydrate. Lanthanum chloride hydrate significantly (p < 0.01) reduced the bone phosphorus burden. Decreases of urinary excretion and increases in fecal excretion of phosphorus indicated a severe phosphorus depletion in all treatments (Al and La). Unfortunately, in the long-term study, lanthanum traces could only be determined in the different tissues but not in plasma. However, in comparison with the equivalent aluminum treatment, the transfer of lanthanum was less important than aluminum transfer. Consequently, lanthanum could provide a possible alternative to aluminum.
本研究的目的是突出一种可能的新型非磷酸铝结合剂，以限制肾衰竭患者的高磷血症。对水合氯化镧作为大鼠饮食磷结合剂进行了评估。六水合氯化铝作为对照进行评估。将动物分为五组（每组6只动物）：1个对照组（C），2个铝组（Al1和Al2），接受不同剂量的六水合氯化铝，以及2个镧组（La1和La2），接受不同剂量的水合氯化镧。在治疗期间，收集尿液和粪便。治疗结束时处死动物，收集血浆和不同器官（肝脏、脾脏、肾脏、大脑和股骨）。为了突出镧在大鼠组织中可能的转移情况，用高剂量进行了一项为期100天的长期研究。治疗结束时，对多个组织（肝脏、脾脏、肾脏、大脑、股骨和肺）进行镧的测定。血浆中磷和钙水平的测定表明，水合氯化镧的效果与六水合氯化铝一样好。水合氯化镧显著（p < 0.01）降低了骨磷负担。磷的尿排泄减少和粪排泄增加表明在所有治疗组（铝组和镧组）中都出现了严重的磷消耗。不幸的是，在长期研究中，仅能在不同组织中检测到镧的痕迹，而在血浆中未检测到。然而，与等效的铝治疗相比，镧的转移比铝的转移要少。因此，镧可能是铝的一种替代物。
